Alterity Therapeutics Limited Share Price Nasdaq
Stocks
ATHE
US02155X2053
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
20:30:00 29/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 2.234 USD | +2.93% |
|
+3.88% | -27.48% |
| 10-05 | Alterity Therapeutics Limited Presents New Analyses of Ath434 Phase 2 Data in Multiple System Atrophy | CI |
| 09-16 | Lake Street Initiates Alterity Therapeutics at Buy With $10 Price Target | MT |
| Market Cap | 41.92M 37.55M 34.64M 31.35M 58.62M 3.99B 59.57M 413M 165M 2.09B 157M 154M 6.62B | P/E 2027 * |
-2.54x | P/E 2028 * | -0.24x |
|---|---|---|---|---|---|
| Enterprise Value | 31.97M 28.63M 26.42M 23.91M 44.7M 3.04B 45.42M 315M 126M 1.59B 120M 117M 5.05B | EV / Sales 2027 * |
25.3x | EV / Sales 2028 * | 2.19x |
| Free-Float |
96.2% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ATHE | Delayed | |
CBOE
| ATHE | Real-time | |
|
Deutsche Boerse AG
| PBN0 | Delayed | |
|
Börse Stuttgart
| PBN0 | Delayed |
Last Transcript: Alterity Therapeutics Limited
| 1 day | +2.93% | ||
| 1 week | +3.88% | ||
| Current month | -38.81% | ||
| 1 month | -38.98% | ||
| 3 months | -49.70% | ||
| 6 months | -51.02% | ||
| Current year | -27.48% |
| 1 week | 2.01 |  | 2.36 |
| 1 month | 2.01 | | 3.57 |
| Current year | 2.01 | | 5.89 |
| 1 year | 2.01 | | 5.89 |
| 3 years | 1 | | 7 |
| 5 years | 1 | | 13.3 |
| 10 years | 1 | | 51.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 06/01/2021 |
| Director of Finance/CFO | - | 29/09/2024 | |
| Chief Tech/Sci/R&D Officer | - | 31/03/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 28/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 07/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 20/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.93% | +3.88% | - | - | 38.71M | |
| +0.34% | +1.12% | +34.75% | +61.06% | 64.14B | |
| +0.98% | +2.68% | +12.25% | +82.98% | 55.53B | |
| +1.75% | +2.01% | +13.30% | +103.69% | 53.03B | |
| -1.43% | -1.17% | +26.27% | +52.86% | 45.99B | |
| -0.48% | -2.80% | +18.01% | +117.99% | 42.45B | |
| +0.82% | +1.37% | +227.94% | +922.41% | 40.45B | |
| -0.26% | -2.57% | +12.55% | +45.18% | 32.25B | |
| -2.07% | +42.73% | +103.77% | +88.74% | 34.47B | |
| -1.20% | -3.28% | +21.10% | -12.28% | 24.23B | |
| Average | +0.09% | +4.29% | +52.22% | +162.51% | 43.62B | |
| Weighted average by Cap. | -0.01% | +3.59% | +49.17% | +160.47% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 1.26M 1.13M 1.04M 945K 1.77M 120M 1.8M 12.46M 4.97M 63.01M 4.74M 4.64M 200M | 2.28M 2.04M 1.88M 1.7M 3.19M 217M 3.24M 22.47M 8.96M 114M 8.55M 8.37M 360M |
| Net income | -27.2M -24.36M -22.48M -20.34M -38.04M -2.59B -38.65M -268M -107M -1.36B -102M -99.91M -4.29B | -29.15M -26.11M -24.09M -21.8M -40.76M -2.78B -41.42M -287M -115M -1.45B -109M -107M -4.6B |
| Net Debt | -9.95M -8.91M -8.22M -7.44M -13.92M -948M -14.14M -98.12M -39.15M -496M -37.35M -36.56M -1.57B | -36.93M -33.08M -30.52M -27.62M -51.64M -3.52B -52.48M -364M -145M -1.84B -139M -136M -5.83B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/10/26 | US$2.234 | +2.93% | 3,789 |
| 28/10/26 | US$2.170 | +1.40% | 23,310 |
| 27/10/26 | US$2.140 | +2.88% | 3,527 |
| 26/10/26 | US$2.080 | -0.48% | 7,914 |
| 23/10/26 | US$2.090 | -2.79% | 26,791 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
- ATHE Stock
Select your edition
All financial news and data tailored to specific country editions
